▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Keith Speights

TMFFishBiz

Keith Speights is a contributing Motley Fool Healthcare Analyst covering publicly traded companies across pharmaceuticals, biotechnology, medical devices, and marijuana. Prior to The Motley Fool, Speights was CEO of Constant Care Technology, a healthcare technology company; vice president of American HealthTech, a healthcare software company; and a director of operations for Blue Cross Blue Shield of Mississippi, a health insurer. He holds a B.S. in Industrial Engineering from Mississippi State University.

Recent Articles by Keith Speights

Marijuana greenhouse

May 28, 2018 by Keith Speights

Better Marijuana Stock: Scotts Miracle-Gro vs. Organigram Holdings

Which stock wins in a match-up between a major supplier to the marijuana industry and an up-and-coming marijuana grower?

Drawing big fish about to gobble smaller fish

May 27, 2018 by Keith Speights

3 Marijuana Stocks That Could Be Gobbled Up Next

More marijuana acquisitions could be on the way. And these three stocks rank high on the list of buyout candidates.

Wall Street sign in front of NYSE

May 27, 2018 by Keith Speights

This Top Marijuana Stock Has Made It to Wall Street -- Is It Time to Buy?

You can now buy Canopy Growth on the NYSE. But should you?

Dividends written in clouds

May 27, 2018 by Keith Speights

Why Iron Mountain Is a Dividend Investor's Dream

This dividend stock has it all.

Businessman touching screen showing heartbeat chart and dollar symbol

May 27, 2018 by Keith Speights

3 Healthcare Stocks That Are Undeniably Dirt Cheap Right Now

These stocks are definitely inexpensive. But are they buys?

Hand touching healthcare button on screen

May 26, 2018 by Keith Speights

Better Buy: Veeva Systems Inc. vs. Cerner

Which stock wins in a head-to-head battle between these two top healthcare technology providers?

Marijuana close-up in greenhouse

May 26, 2018 by Keith Speights

Better Marijuana Stock: Cronos Group vs. Emerald Health Therapeutics

Which stock wins in a head-to-head matchup between these two Canadian marijuana growers?

Doctor holding card with diabetes

May 25, 2018 by Keith Speights

How to Invest in Diabetes Stocks

Here's everything you need to know about investing in the fast-growing diabetes market.

Man behind stock chart

May 25, 2018 by Keith Speights

3 Likely Reasons Geron Stock Is Sizzling Hot Right Now

This biotech stock is skyrocketing. Here's why -- maybe.

Dollar signs on drawing of steps

May 24, 2018 by Keith Speights

Why Wall Street Analysts Think This Biotech Stock Could Nearly Double

Cara Therapeutics hopes to still succeed with a drug that's failed once already.

Scientists in lab - medical research

May 24, 2018 by Keith Speights

Better Buy: Bellicum Pharmaceuticals, Inc. vs. bluebird bio

Which stock wins in a head-to-head match-up between these two clinical-stage biotechs?

Puzzled businessman

May 23, 2018 by Keith Speights

Warren Buffett's Mentor Was Right About the Crazy Market -- and 2 Biotech Stocks Prove It

The reaction to news from Celgene and Insys demonstrates an undeniable truth: Mr. Market can be very irrational at times.

Marijuana leaves inside medical capsules

Jul 16, 2018 by Keith Speights

This Latest Marijuana Survey Should Be Great News for Cannabis-Focused Biotechs

No pain, big gain? There could be an untapped market for cannabinoids that biotechs aren't aggressively pursuing yet.

Test tube and question mark

May 23, 2018 by Keith Speights

Is Acadia Pharmaceuticals (ACAD) a Buy?

Is there a silver lining in the dark clouds hovering over this biotech stock?

Face of scientist in lab with beaker

May 23, 2018 by Keith Speights

Better Buy: AbbVie Inc. vs. Pfizer Inc.

Which big pharma stock wins in a head-to-head match-up?

Jeff Sessions - DOJ

May 22, 2018 by Keith Speights

Jeff Sessions Thwarted Again -- but Will It Help Marijuana Stocks?

The Attorney General still won't be able to target states that have legalized medical marijuana. But don't count on a boost for marijuana stocks.

FDA

May 22, 2018 by Keith Speights

3 Biotechs on the FDA's Naughty List That Should Be on Investors' Buy Lists

The FDA might be down on these biotechs, but investors shouldn't be.

May 22, 2018 by Keith Speights

3 Warren Buffett Stocks With Dividend Yields Over 4%

But are these high-yielding stocks in the billionaire investor's portfolio smart picks for the rest of us?

IPO on chalkboard

May 20, 2018 by Keith Speights

This Was the Biggest Marijuana IPO in History -- but Is the Stock a Buy?

You can now buy The Green Organic Dutchman stock. But should you?

Marijuana buds, cigarettes, and Canadian maple leaf

May 20, 2018 by Keith Speights

How Big Will the Canadian Recreational Marijuana Market Be? Colorado Could Give a Clue

Recreational marijuana in Canada could generate more money than you think.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services